利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

37 条记录 (耗时 0.029 秒)

    C peptide for improved preparation of insulin and insulin analogs
    21.
    发明授权
    C peptide for improved preparation of insulin and insulin analogs 有权
    C肽用于改善胰岛素和胰岛素类似物的制备

    公开(公告)号：US06534288B1

    公开(公告)日：2003-03-18

    申请号：US09676787

    申请日：2000-10-02

    申请人： Paul Habermann ,  Johann Ertl ,  Johannes Meiwes ,  Gerhard Seipke

    发明人： Paul Habermann ,  Johann Ertl ,  Johannes Meiwes ,  Gerhard Seipke

    IPC分类号： C12N1500

    CPC分类号： C07K14/62 ,  C07K2319/00

    摘要： The invention relates to a precursor of human insulin or of an insulin analog of the formula I: Fus-B(1-30)-RDVP-Yn-A(1-21)  (I); wherein Fus is an optionally present fusion portion; B(1-30) is a B chain of human insulin, Y is an amino acid chain which terminates with a basic amino acid at the C terminus; n is from 2 to 50 and indicates the length of the amino acid chain Y; and A(1-21) is an A chain of human insulin, and the A chain and/or the B chain can be modified by amino acid substitution, deletions and/or additions. The present invention also provides DNA coding for the above precursors, preparation and use of the instant precursors and DNA, and a process for preparing human insulin or an insulin analog.

    摘要翻译： 本发明涉及人胰岛素或式I的胰岛素类似物的前体：其中Fus是任选存在的融合部分; B（1-30）是人胰岛素的B链，Y是氨基酸链，其以 C末端的碱性氨基酸; n为2-50，表示氨基酸链Y的长度; A（1-21）是人胰岛素的A链，A链和/或B链可以通过氨基酸取代，缺失和/或添加进行修饰。 本发明还提供编码上述前体的DNA，即制备和使用本发明的前体和DNA，以及制备人胰岛素或胰岛素类似物的方法。

    Insulin derivatives with increased zinc binding
    22.
    发明授权
    Insulin derivatives with increased zinc binding 失效
    具有增加的锌结合的胰岛素衍生物

    公开(公告)号：US06221837B1

    公开(公告)日：2001-04-24

    申请号：US08900574

    申请日：1997-07-25

    申请人： Johann Ertl ,  Paul Habermann ,  Karl Geisen ,  Gerhard Seipke

    发明人： Johann Ertl ,  Paul Habermann ,  Karl Geisen ,  Gerhard Seipke

    IPC分类号： C07K1462

    CPC分类号： C07K14/62 ,  A61K38/00 ,  Y10S514/866

    摘要： Insulin derivatives with increased zinc binding where Z is a histidine residue or a peptide having 2 to 35 genetically encodable amino acid residues, having 1 to 5 histidine residues, are suitable for the production of pharmaceutical preparations for the treatment of diabetes. Insulins of the formula I form complexes with zinc++, comprising an insulin hexamer and approximately 5 to 9 mol of zinc++ per hexamer.

    摘要翻译： 具有增加的锌结合的胰岛素衍生物，其中Z是组氨酸残基或具有2至35个具有1至5个组氨酸残基的2至35个遗传编码氨基酸残基的肽，适用于制备用于治疗糖尿病的药物制剂。 式I的胰岛素与锌++形成复合物，其包含胰岛素六聚体和约5至9摩尔锌++每六聚体。

    Fusion proteins capable of being secreted into a fermentation medium
    25.
    发明授权
    Fusion proteins capable of being secreted into a fermentation medium 有权
    能够分泌到发酵培养基中的融合蛋白

    公开(公告)号：US07202059B2

    公开(公告)日：2007-04-10

    申请号：US10076634

    申请日：2002-02-19

    申请人： Paul Habermann ,  Johann Ertl

    发明人： Paul Habermann ,  Johann Ertl

    IPC分类号： C12P21/04 ,  C07H21/04

    CPC分类号： C12N15/625 ,  C07K14/62 ,  C07K14/815 ,  C07K2319/035 ,  C07K2319/75 ,  C12N15/74

    摘要： Fusion protein including a fusion part and a protein of interest, the combination of the two proteins leading to the fusion protein being secreted into a supernatant of a bacterial host with the protein of interest being present in its correct three-dimensional structure. Nucleic acid including a sequence coding for a fusion protein, the sequence including: —F—Asm—Rn—Y—, where F is a nucleic acid sequence coding for an amino acid sequence which allows secretion of a protein encoded by Y into a fermentation medium, As is a chemical bond or a nucleic acid sequence comprising a codon, m is an integer from 0–10, R is a chemical bond or an arginine codon, n is 0 or 1, and Y is a nucleic acid sequence coding for a protein of interest. Processes therefor.

    摘要翻译： 融合蛋白包括融合部分和感兴趣的蛋白质，导致融合蛋白的两种蛋白质的组合分泌到细菌宿主的上清液中，其中感兴趣的蛋白质以其正确的三维结构存在。 包含编码融合蛋白的序列的核酸，所述序列包括：-F-As m -R n -Y-，其中F是编码 允许由Y编码的蛋白质分泌到发酵培养基中的氨基酸序列As是化学键或包含密码子的核酸序列，m是0-10的整数，R是化学键或精氨酸密码子 ，n为0或1，Y为编码感兴趣的蛋白质的核酸序列。 流程。

    Insulin derivatives having a rapid onset of action
    26.
    发明授权
    Insulin derivatives having a rapid onset of action 失效
    具有快速起效的胰岛素衍生物

    公开(公告)号：US06221633B1

    公开(公告)日：2001-04-24

    申请号：US09099307

    申请日：1998-06-18

    申请人： Johann Ertl ,  Paul Habermann ,  Karl Geisen ,  Gerhard Seipke

    发明人： Johann Ertl ,  Paul Habermann ,  Karl Geisen ,  Gerhard Seipke

    IPC分类号： C12N1517

    CPC分类号： C07K14/62 ,  A61K38/00 ,  C07K2319/00 ,  Y10S514/866

    摘要： The present invention relates to insulin derivatives which in comparison to human insulin, have an accelerated onset of action, to a process for their preparation and to their use, in particular in pharmaceutical preparations for the treatment of diabetes mellitus. In particular, the present invention relates to insulin derivatives or physiologically tolerable salts thereof in which asparagine (Asn) in position B3 of the B chain is replaced by a naturally occurring basic amino acid residue and at least one amino acid residue in the positions B27, B28 or B29 of the B chain is replaced by another naturally occurring amino acid residue, it optionally being possible for asparagine (Asn) in position 21 of the A chain to be replaced by Asp, Gly, Ser, Thr or Ala and for phenylalanine (Phe) in position B1 of the B chain and the amino acid residue in position B30 of the B chain to be absent.

    摘要翻译： 本发明涉及与人胰岛素相比，加速起效的胰岛素衍生物，其制备方法及其用途，特别是用于治疗糖尿病的药物制剂中。 特别地，本发明涉及胰岛素衍生物或其生理上可耐受的盐，其中B链B3位的天冬酰胺（Asn）被天然存在的碱性氨基酸残基和B27位置的至少一个氨基酸残基所取代， B链的B28或B29被另一个天然存在的氨基酸残基替代，其任选可能是由A，A，D，Gly，Ser，Thr或Ala代替的A链的第21位的天冬酰胺（Asn）和苯丙氨酸 Phe）在B链的位置B1和B链的位置B30的氨基酸残基不存在。

    Amidated insulin glargine
    29.
    发明授权
    Amidated insulin glargine 有权
    酰化甘精胰岛素

    公开(公告)号：US08048854B2

    公开(公告)日：2011-11-01

    申请号：US12349864

    申请日：2009-01-07

    申请人： Paul Habermann ,  Frank Zocher

    发明人： Paul Habermann ,  Frank Zocher

    IPC分类号： A61K38/28 ,  C07K14/62

    CPC分类号： C07K14/62 ,  A61K38/00

    摘要： The invention relates to insulin glargine which is modified by amidation, especially Gly(A21), Arg(B31), Arg amide (B32) human insulin (insulin glargine amide).

    摘要翻译： 本发明涉及通过酰胺化，特别是Gly（A21），Arg（B31），Arg酰胺（B32）人胰岛素（甘精胰岛素酰胺）修饰的甘精胰岛素。